Testing SX-682 plus apalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs (SX-682 and apalutamide) for men with metastatic prostate cancer that is no longer responding to standard hormone therapy. The goal is to see if adding SX-682 can help apalutamide work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic prostate cancer that is still growing despite low testosterone levels (castration-resistant).
- You must have had at least 12 weeks of a newer antiandrogen drug (like enzalutamide, apalutamide, or darolutamide) and your cancer progressed during that treatment.
- Your PSA level must be 10 or higher.
- You must be able to swallow pills and be willing to have biopsies before and during treatment (for phase 1).
- You must not have a history of seizures, uncontrolled heart problems, or certain other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines for advanced prostate cancer that has spread and is no longer responding to current hormone therapy. The goal is to see if adding the experimental drug mevrometostat to enzalutamide helps control the cancer better.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This trial tests whether adding surgery to remove the prostate and radiation to visible cancer spots, along with the usual hormone therapy, can help men with newly diagnosed prostate cancer that has spread. It aims to see if this more intensive approach can improve outcomes.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Hear when a new Metastatic Castrate Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.